FDAnews Drug Daily Bulletin

REPLIGEN Q4 NET LOSS WIDENS ON LOWER REVENUES, HIGHER OPERATING EXPENSES

June 9, 2006
A A

Thursday morning, Repligen Corp., a biopharmaceutical company, revealed fourth quarter results, reporting a net loss that widened on higher operating expenses and on a 4% decline in revenues.
Trading Markets